Clinical implications of the serum CA19-9 level in “biological borderline resectability” and “biological downstaging” in the setting of preoperative chemoradiation therapy for pancreatic cancer
Hidenori Takahashi(Osaka International Cancer Institute), Osamu Ishikawa(Gunma University), Masahiko Yano(Nagoya Sangyo University), Kei Asukai(Osaka International Cancer Institute), Masayuki Ohue(Hyogo Medical University), Hiroshi Wada, Hiroshi Miyata(Osaka University), Kazuyoshi Yamamoto(Osaka International Cancer Institute), Masato Sakon(Osaka University), Junichi Nishimura, Naoki Shinno(Osaka International Cancer Institute), Keijiro Sugimura(Osaka International Cancer Institute), Masayoshi Yasui(Osaka International Cancer Institute), Shinichiro Hasegawa(Osaka International Cancer Institute), Takeshi Omori(Osaka International Cancer Institute), Naotsugu Haraguchi(Nara City Hospital), Hisashi Hara(Sakai Municipal Hospital), Hajime Ushigome(Osaka International Cancer Institute), Daisaku Yamada(Osaka International Cancer Institute)
Cited by 63
Related Papers
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Practical Usefulness of Lymphatic and Connective Tissue Clearance for the Carcinoma of the Pancreas Head
|Annals of Surgery|1988|373
Genome-wide Expression Analysis of Mouse Liver Reveals CLOCK-regulated Circadian Output Genes
|Journal of Biological Chemistry|2003|347
A novel image‐guided surgery of hepatocellular carcinoma by indocyanine green fluorescence imaging navigation
|Journal of Surgical Oncology|2009|333
Application of sentinel node biopsy to gastric cancer surgery
|Surgery|2001|268